• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泌尿系统癌症骨转移患者的骨骼相关事件:日本多中心研究。

Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan.

机构信息

Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

出版信息

Int J Urol. 2010 Apr;17(4):332-6. doi: 10.1111/j.1442-2042.2010.02468.x. Epub 2010 Feb 25.

DOI:10.1111/j.1442-2042.2010.02468.x
PMID:20202004
Abstract

OBJECTIVE

To investigate the incidence of skeletal-related events (SRE) in urological cancer patients with bone metastases in Japan.

METHODS

Five hundred eleven patients with urological cancer and documented bone metastases treated from January 2003 to April 2008 in ten Japanese institutions were included in a retrospective analysis. Type and incidence of SRE (fracture, radiotherapy, spinal cord compression, surgery, hypercalcemia, and bone pain) were determined from patient medical records.

RESULTS

The overall incidence of SRE, including 'pain', was 61%. The most common event was radiotherapy for bone metastases, with an incidence of 31%. The overall incidence of events seemed to be similar among Japanese and Western patients with prostate cancer and renal cell carcinoma when comparing data with previously published reports. Nevertheless, a much lower incidence of fracture (19.1%) was observed in Japanese renal cell carcinoma patients.

CONCLUSIONS

The overall incidence of SRE in Japanese urological cancer patients with bone metastasis was similar to that in Western patients, but the incidence of fracture was lower in Japanese renal cancer patients.

摘要

目的

调查日本骨转移泌尿癌症患者骨骼相关事件(SRE)的发生率。

方法

对 2003 年 1 月至 2008 年 4 月在日本 10 家机构接受治疗的 511 例有骨转移记录的泌尿癌症患者进行回顾性分析。从患者病历中确定 SRE(骨折、放疗、脊髓压迫、手术、高钙血症和骨痛)的类型和发生率。

结果

SRE(包括“疼痛”)的总发生率为 61%。最常见的事件是骨转移的放疗,发生率为 31%。与之前发表的报告相比,当比较日本和西方前列腺癌和肾细胞癌患者的数据时,似乎日本患者中所有类型事件的总发生率相似。然而,日本肾细胞癌患者的骨折发生率(19.1%)明显较低。

结论

日本骨转移泌尿癌症患者的 SRE 总发生率与西方患者相似,但日本肾癌患者的骨折发生率较低。

相似文献

1
Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan.泌尿系统癌症骨转移患者的骨骼相关事件:日本多中心研究。
Int J Urol. 2010 Apr;17(4):332-6. doi: 10.1111/j.1442-2042.2010.02468.x. Epub 2010 Feb 25.
2
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.唑来膦酸可延缓晚期肾细胞癌患者骨相关事件的发生及骨骼疾病的进展。
Cancer. 2003 Sep 1;98(5):962-9. doi: 10.1002/cncr.11571.
3
The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.肺癌骨转移患者骨相关事件的治疗费用。
Oncology. 2004;67(5-6):390-6. doi: 10.1159/000082923.
4
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.唑来膦酸治疗多发性骨髓瘤和癌症骨转移的批准摘要。
Clin Cancer Res. 2003 Jul;9(7):2394-9.
5
Bisphosphonates: clinical experience.双膦酸盐类药物:临床经验
Oncologist. 2004;9 Suppl 4:14-27. doi: 10.1634/theoncologist.9-90004-14.
6
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.肾细胞癌骨转移患者的骨骼并发症及唑来膦酸的治疗益处
Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6397S-403S. doi: 10.1158/1078-0432.CCR-040030.
7
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.两项关于帕米膦酸二钠缓解转移性前列腺癌男性骨痛的多中心、随机、安慰剂对照研究的联合分析。
J Clin Oncol. 2003 Dec 1;21(23):4277-84. doi: 10.1200/JCO.2003.05.147. Epub 2003 Oct 27.
8
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.接受化疗的非小细胞肺癌患者发生骨相关事件的危险因素。
Lung Cancer. 2009 Aug;65(2):219-22. doi: 10.1016/j.lungcan.2008.10.026. Epub 2008 Dec 10.
9
Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.肾细胞癌骨转移的放疗,联合或不联合唑来膦酸。
BJU Int. 2009 Mar;103(5):620-4. doi: 10.1111/j.1464-410X.2008.08124.x. Epub 2008 Oct 16.
10
Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.与前列腺癌伴骨转移患者骨骼相关事件相关的医疗保健利用和费用。
Prostate Cancer Prostatic Dis. 2013 Mar;16(1):23-7. doi: 10.1038/pcan.2012.42. Epub 2012 Nov 13.

引用本文的文献

1
Bone metastases from urothelial carcinoma. The dark side of the moon.尿路上皮癌的骨转移。月球的阴暗面。
J Bone Oncol. 2021 Nov 28;31:100405. doi: 10.1016/j.jbo.2021.100405. eCollection 2021 Dec.
2
Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis.放疗联合唑来膦酸可降低骨转移肾癌患者的骨骼相关事件。
Int J Clin Oncol. 2018 Dec;23(6):1127-1133. doi: 10.1007/s10147-018-1310-7. Epub 2018 Jun 29.
3
Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis.
尿路上皮癌骨转移患者的骨相关事件与预后
Int J Clin Oncol. 2017 Jun;22(3):548-553. doi: 10.1007/s10147-016-1075-9. Epub 2017 Jan 2.
4
Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.在有乳腺癌、肺癌或前列腺癌和骨转移的患者中,骨骼相关事件的自然史:两个美国大型卫生系统的 15 年研究。
Support Care Cancer. 2013 Dec;21(12):3279-86. doi: 10.1007/s00520-013-1887-3. Epub 2013 Jul 25.